NYSE - Delayed Quote USD

Bio-Rad Laboratories, Inc. (BIO-B)

279.91 0.00 (0.00%)
As of April 18 at 3:59 PM EDT. Market Open.
Loading Chart for BIO-B
DELL
  • Previous Close 279.91
  • Open 281.55
  • Bid 276.05 x 1400
  • Ask 286.14 x 800
  • Day's Range 279.91 - 281.55
  • 52 Week Range 271.00 - 467.95
  • Volume 5
  • Avg. Volume 275
  • Market Cap (intraday) 7.882B
  • Beta (5Y Monthly) 0.88
  • PE Ratio (TTM) --
  • EPS (TTM) -21.83
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

www.bio-rad.com

8,030

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BIO-B

Performance Overview: BIO-B

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BIO-B
12.71%
S&P 500
7.02%

1-Year Return

BIO-B
39.69%
S&P 500
25.38%

3-Year Return

BIO-B
53.42%
S&P 500
22.12%

5-Year Return

BIO-B
8.67%
S&P 500
74.46%

Compare To: BIO-B

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIO-B

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    7.88B

  • Enterprise Value

    7.68B

  • Trailing P/E

    --

  • Forward P/E

    25.13

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.06

  • Price/Book (mrq)

    0.91

  • Enterprise Value/Revenue

    2.88

  • Enterprise Value/EBITDA

    -11.73

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -23.86%

  • Return on Assets (ttm)

    1.77%

  • Return on Equity (ttm)

    -6.94%

  • Revenue (ttm)

    2.67B

  • Net Income Avi to Common (ttm)

    -637.32M

  • Diluted EPS (ttm)

    -21.83

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.61B

  • Total Debt/Equity (mrq)

    16.08%

  • Levered Free Cash Flow (ttm)

    170.82M

Company Insights: BIO-B

Fair Value

279.91 Current
 

Dividend Score

0 Low
BIO-B
Sector Avg.
100 High
 

Hiring Score

0 Low
BIO-B
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
BIO-B
Sector Avg.
100 High
 

People Also Watch